RGNT (Regentis Biomaterials) 3-Year Share Buyback Ratio: -1.70% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RGNT Regentis Biomaterials Ltd RGNT
14 GF Score
Price $2.00
! 2 Warning Signs
View Full Analysis

What is Regentis Biomaterials 3-Year Share Buyback Ratio?

Regentis Biomaterials RGNT +5.26% 14 3-Year Share Buyback Ratio is -1.70 as of Dec. 2025. GuruFocus rates RGNT with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 614 Medical Devices & Instruments companies, Regentis Biomaterials ranks better than 55.54% on this metric.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Regentis Biomaterials's current 3-Year Share Buyback Ratio was -1.70%.

The historical rank and industry rank for Regentis Biomaterials's 3-Year Share Buyback Ratio or its related term are showing as below:

RGNT' s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -1.7   Med: 0   Max: 0
Current: -1.7

During the past 6 years, Regentis Biomaterials's highest 3-Year Share Buyback Ratio was 0.00%. The lowest was -1.70%. And the median was 0.00%.

RGNT's 3-Year Share Buyback Ratio is ranked better than
55.54% of 614 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs RGNT: -1.70

Regentis Biomaterials (AMEX:RGNT) 3-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.


Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.


Regentis Biomaterials 3-Year Share Buyback Ratio Related Terms


RGNT vs BNGO, ZJYL, UEEC: 3-Year Share Buyback Ratio Comparison

For the Medical Instruments & Supplies subindustry, Regentis Biomaterials's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regentis Biomaterials 3-Year Share Buyback Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Regentis Biomaterials's 3-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Regentis Biomaterials's 3-Year Share Buyback Ratio falls into.


RGNT
14GF Score
Regentis Biomaterials Ltd RGNT
3-Year Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Regentis Biomaterials 3-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

What does a 3-Year Share Buyback Ratio of -1.70 mean?
Regentis Biomaterials (RGNT) has a 3-Year Share Buyback Ratio of -1.70 as of Dec. 2025. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Regentis Biomaterials and its competitors. According to the industry distribution chart, Regentis Biomaterials ranks #273 out of 614 companies in the Medical Devices & Instruments industry, placing it in the top 44.5%.
Is Regentis Biomaterials' 3-Year Share Buyback Ratio too high?
Regentis Biomaterials' current 3-Year Share Buyback Ratio is -1.70. Based on the distribution chart, Regentis Biomaterials ranks #273 out of 614 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Regentis Biomaterials has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regentis Biomaterials' 3-Year Share Buyback Ratio compare to BNGO and ZJYL?
According to the Medical Devices & Instruments industry distribution chart, Regentis Biomaterials ranks #273 out of 614 companies for 3-Year Share Buyback Ratio. This puts Regentis Biomaterials in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Medical Devices & Instruments company?
A good 3-Year Share Buyback Ratio depends on the Medical Devices & Instruments industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for Regentis Biomaterials and its competitors. Regentis Biomaterials's current 3-Year Share Buyback Ratio is -1.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regentis Biomaterials stock overvalued right now?
Regentis Biomaterials (RGNT) has a current 3-Year Share Buyback Ratio of -1.70. The current 3-Year Share Buyback Ratio is -1.70. Regentis Biomaterials' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For Regentis Biomaterials (RGNT), the current 3-Year Share Buyback Ratio is -1.70 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regentis Biomaterials Business Description

Address 60, Medinat Hyahudim, Entrance C, Herzlia Pituach, ISR, 4676652
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articular knee cartilage.
14GF Score

Get the complete analysis for RGNT

3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.00
Price